Eliaz Therapeutics
Santa Rosa
About Eliaz Therapeutics
ETI have developed a patented, unique medical device that removes galectin-3 from human blood. The device removes both bound and free galectin-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies. The single-use apheresis column selectively removes Galectin-3 from the body. It contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Seed (Sep 2025)
- Website: eliaztherapeutics.com
- Phone: (707)542-5900
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/eliaz-therapeutics-21329 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.